The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS).

被引：0
|
作者：
Pignochino, Ymera [1 ]
Capozzi, Federica [2 ]
Dell'aglio, Carmine [2 ]
Basirico, Marco [2 ]
D'ambrosio, Lorenzo [2 ]
Galizia, Danilo [2 ]
Palesandro, Erica [2 ]
Benassi, Maria Serena [3 ]
Aglietta, Massimo [2 ]
Grignani, Giovanni [4 ]
机构：
[1] Univ Turin, Fdn Piemonte Oncol, Candiolo, Italy
[2] Univ Turin, Candiolo, Italy
[3] Ist Ortoped Rizzoli, Bologna, Italy
[4] FPO, Candiolo, Italy
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB213
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models of bone and soft tissue sarcoma (BSTS).
    Pignochino, Ymera
    Capozzi, Federica
    Aglio, Carmine Dell'
    Basiric, Marco
    Lorenzato, Annalisa
    D'Ambrosio, Lorenzo
    Galizia, Danilo
    Gammaitoni, Loretta
    Piana, Raimondo
    Benassi, Maria Serena
    Sangiolo, Dario
    Aglietta, Massimo
    Grignani, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Efficacy and tolerability of trabectedin in heavily pretreated soft tissue sarcomas (STS)
    Alonso, Teresa
    Gajate, Pablo
    Casado, Antonio
    Segura Gonzalez, Eduardo Raul
    Ortega, Luis
    Luis Cebrian, Juan
    Talavera, Pablo
    Zugazagoitia, Jon
    Acosta, Daniel
    Diaz-Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Preclinical study of trabectedin (TR) and poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS)
    Pignochino, Ymera
    Capozzi, Federica
    Aglio, Carmine Dell'
    Basirico, Marco
    Tarraran, Loredana
    D'Ambrosio, Lorenzo
    Galizia, Danilo
    Palesandro, Erica
    Gammaitoni, Loretta
    Sangiolo, Dario
    Benassi, Maria Serena
    Aglietta, Massimo
    Grignani, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas
    Pignochino, Y.
    Capozzi, F.
    Dell'Aglio, C.
    Basirico, M.
    D'ambrosio, L.
    Galizia, D.
    Palesandro, E.
    Benassi, M. S.
    Aglietta, M.
    Grignani, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 107 - 107
  • [5] Antitumor Activity of Polyuridylic Acid in Human Soft Tissue and Bone Sarcomas
    Adepoju, Linda J.
    Geiger, James D.
    JOURNAL OF SURGICAL RESEARCH, 2010, 164 (01) : E107 - E114
  • [6] Prediction of therapy resistance in preclinical PDX models of soft tissue sarcomas
    Rolff, J.
    Traub, F.
    Werner, M.
    Tunn, P-U
    Hoffmann, J.
    Fichtner, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 159 - 159
  • [7] Preclinical models of soft tissue sarcomas - generation and applications to enhance translational research
    Pasquali, Sandro
    Moura, David S.
    Danks, Molly R.
    Manasterski, Piotr J.
    Zaffaroni, Nadia
    Stacchiotti, Silvia
    Mondaza-Hernandez, Jose L.
    Kerrison, William G. J.
    Martin-Broto, Javier
    Huang, Paul H.
    Brunton, Valerie G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
  • [8] DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
    Merlini, Alessandra
    Centomo, Maria Laura
    Ferrero, Giulio
    Chiabotto, Giulia
    Miglio, Umberto
    Berrino, Enrico
    Giordano, Giorgia
    Brusco, Silvia
    Pisacane, Alberto
    Maldi, Elena
    Sarotto, Ivana
    Capozzi, Federica
    Lano, Cristina
    Isella, Claudio
    Crisafulli, Giovanni
    Aglietta, Massimo
    Dei Tos, Angelo Paolo
    Sbaraglia, Marta
    Sangiolo, Dario
    D'Ambrosio, Lorenzo
    Bardelli, Alberto
    Pignochino, Ymera
    Grignani, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Chemotherapy for heavily pretreated patients (pts.) with bone (BS) and soft tissue (STS) sarcomas
    Reichardt, P
    Tilgner, J
    Gabor, C
    Dorken, B
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 494 - 494
  • [10] Pharmacokinetics of trabectedin and olaparib given in combination during a phase 1b trial (NCT 02398058) in patients with advanced and non-resectable bone and soft tissue sarcomas
    Matteo, C.
    Zucchetti, M.
    D'Ambrosio, L.
    Pignochino, Y.
    Dovrtelova, G.
    Tolomeo, F.
    Merlini, A.
    Picci, P.
    Palmerini, E.
    D'incalci, M.
    Grignani, G.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E58 - E58
12345